POSACONAZOLE-DRLA posaconazole 100 mg modified release tablet blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

posaconazole, Quantity: 100 mg

Commercializzato da:

Dr Reddys Laboratories Australia Pty Ltd

Forma farmaceutica:

Tablet, modified release

Composizione:

Excipient Ingredients: hyprolose; iron oxide red; purified talc; microcrystalline cellulose; macrogol 400; hypromellose acetate succinate; magnesium stearate; triacetin; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose

Via di somministrazione:

Oral

Confezione:

24, 96

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

POSACONAZOLE-DRLA (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ,? Invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ,? Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. ,POSACONAZOLE-DRLA is also indicated for the: ,? Prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients.

Dettagli prodotto:

Visual Identification: Brown, capsule-shaped, bevelled edge, film-coated tablet, debossed with '470' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2020-07-24